The new device is smarter, 20% more powerful and 50% smaller; also, the companion app has been revamped from the ground up.

NeuroMetrix has unveiled what it says is its "latest breakthrough for the treatment of chronic pain," Quell 2.0, which takes the company's existing FDA-cleared nerve stimulation technology to a new level. The Quell 2.0 device is smarter, more powerful and 50% smaller; whereas the Quell app has been totally redesigned to make it easier to use.

Quell is worn on the upper calf and activates the body's natural pain relief response. It is designed to be used during the day while active and at night while sleeping.

Inside, Quell 2.0 packs a custom neurostimulation microchip that includes all the personalization features of the prior Quell device and now also automatically adapts to changes in body position and can sense when you put the device on and automatically start therapy. It is also 20% more powerful than the prior Quell device.

As for the app, it is now easier to use, enabling users to calibrate Quell to their needs, start and stop therapy, choose a variety of customization and automation features, and track therapy, sleep, activity and pain.

"Since first launching Quell in 2015, over 100,000 individuals living with chronic pain have experienced Quell's patented neurotechnology. Feedback from our customers and new research has enabled us to create a more intelligent, powerful and compact device," Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, said in a statement. "We believe that technology can have a positive impact on chronic pain and look forward to helping even more consumers find relief with Quell 2.0."